Lanreotide treatment in a patient with interferon-associated Graves' ophthalmopathy
Journal
Graefe's Archive for Clinical and Experimental Ophthalmology
Journal Volume
243
Journal Issue
3
Pages
269-272
Date Issued
2005
Author(s)
Abstract
Background: We report a case of Graves' ophthalmopathy (GO) developed after the administration of interferon-α for chronic hepatitis C. Methods: The GO was treated with lanreotide. Results: A 47-year-old female patient presented with euthyroid GO with spontaneous retrobulbar pain, eyelid edema, conjunctival injection and eyelid retraction of the right eye and conjunctival injection of the left eye 6 months after administration of interferon-α for chronic hepatitis C. Orbital computed tomography revealed no involvement of extraorbital muscles and no increase in retrobulbar adipose tissue. Only soft tissue was involved. These symptoms subsided after 12 weeks of lanreotide treatment, except right eyelid retraction, which, however, disappeared later during follow-up. Conclusion: The use of interferon-α may be complicated by GO and lanreotide might be considered for GO if patients cannot accept steroid therapy. ? Springer-Verlag 2004.
SDGs
Other Subjects
alpha interferon; angiopeptin; artificial tear; octreotide; recombinant alpha2b interferon; ribavirin; somatostatin derivative; steroid; adult; anemia; article; case report; clinical feature; computer assisted tomography; endocrine ophthalmopathy; euthyroidism; eyelid edema; eyelid retraction; female; hepatitis C; human; leukopenia; priority journal; Antiviral Agents; Drug Therapy, Combination; Female; Graves Disease; Hepatitis C, Chronic; Humans; Interferon-alpha; Middle Aged; Peptides, Cyclic; Ribavirin; Somatostatin; Tomography, X-Ray Computed; Treatment Outcome
Type
journal article